ClinicalTrials.gg

Program

Fluconazole

Also written as “fluconazole”, “Fluconazole 400 mg” and “Diflucan®”.

Its studies are mostly in Meningitis, Cryptococcal · Candidiasis · Candidiasis, Oral · Candidemia · Lymphoma, led by 8 companies.

Furthest: phase 3, since Nov 2, 199937 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer260 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
Merck30 open or runningphase 3since Nov 2, 1999Nov 2, 1999none ahead
AstraZeneca20 open or runningphase 1since Mar 20, 2014Mar 20, 2014none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since Jan 13, 2012Jan 13, 2012none ahead
Bayer10 open or runningphase 1since Apr 17, 2019Apr 17, 2019none ahead
Johnson & Johnson10 open or runningno phasesince Nov 2, 1999Nov 2, 1999none ahead
Pharmtechnology10 open or runningphase 1since Jul 26, 2019Jul 26, 2019none ahead
Sutphin Drugs10 open or runningearly phase 1since Jul 31, 2020Jul 31, 2020none ahead

Also a collaborator on its studies: altasciences-company-inc, impact-biomedicines-inc-a-wholly-owned-subsidiary-of-celgene and vicuron-pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 22 studies since Nov 2, 1999.

  1. Mar 11, 2003Phase 3 study in CandidiasisPfizer · NCT00056368 · 256 enrolled · United States
  2. Mar 25, 2008Phase 3 study in Tinea CapitisPfizer · NCT00645242 · 185 enrolled · United States, Puerto Rico
  3. May 29, 2008Phase 3 study in Candidiasis, InvasivePfizer · NCT00689338 · 216 enrolled · Austria, Belgium, Canada and more
  4. Dec 18, 2008Phase 3 study in LeukopeniaMerck · NCT00811928 · 252 enrolled
  5. Aug 3, 2010Phase 3 study in CandidemiaPfizer · NCT01176058 · 17 enrolled · China
  6. Jan 13, 2012Dr. Reddy's Laboratories's first studies: 2 phase 1 studies in HealthyNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT01511770, NCT01511757
  7. Jan 28, 2013Phase 3 study in Candidiasis, VulvovaginalPfizer · NCT01806623 · 157 enrolled · Japan
  8. Mar 20, 2014AstraZeneca's first study: phase 1 study in Solid TumoursNew to AstraZenecaAstraZeneca · NCT02093728 · 26 enrolled · United States
  9. Aug 20, 2014Phase 1 study in NeoplasmsPfizer · NCT02222922 · 138 enrolled · United States, Spain
  10. Aug 3, 2018Phase 1 study in BioequivalencePfizer · NCT03621072 · 36 enrolled · China
  11. Apr 17, 2019Bayer's first study: phase 1 study in Pharmacology, ClinicalNew to BayerBayer · NCT03929861 · 26 enrolled · Germany
  12. Jul 26, 2019Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT04038008 · 26 enrolled · Canada
  13. Jul 31, 2020Sutphin Drugs's first study: early phase 1 study in CandidiasisNew to Sutphin DrugsSutphin Drugs · NCT04502277 · 200 enrolled · United States, India
  14. Nov 17, 2021Phase 1 study in Healthy VolunteersAstraZeneca · NCT05140096 · 30 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Cytochrome P450 51 inhibitor”ChEMBL 37, by rule

Studies

All 37 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05140096Healthy Volunteers · United States1CompletedAstraZenecaApr 15, 202030
NCT04502277Candidiasis · United States, IndiaEarly 1UNKNOWNSutphin DrugsDec 31, 2020200
NCT04038008Bioequivalence · Canada1CompletedPharmtechnologySep 17, 201926
NCT03929861Pharmacology, Clinical · Germany1CompletedBayerSep 10, 201226
NCT03621072Bioequivalence · China1CompletedPfizerJul 20, 201936
NCT02222922Neoplasms · United States, Spain1CompletedPfizerNov 5, 2019138
NCT02093728Solid Tumours · United States1CompletedAstraZenecaJun 201426
NCT01806623Candidiasis, Vulvovaginal · Japan3CompletedPfizerNov 22, 2013157
NCT01511770Healthy · Canada1CompletedDr. Reddy's LaboratoriesAug 200217
NCT01511757Healthy · Canada1CompletedDr. Reddy's LaboratoriesJun 200215
NCT01176058Candidemia · China3TerminatedPfizerNov 201117
NCT00811928Leukopenia3CompletedMerckMay 2010252
NCT00689338Candidiasis, Invasive · Austria, Belgium, Canada and more3CompletedPfizerMay 2010216
NCT00645242Tinea Capitis · United States, Puerto Rico3CompletedPfizer185
NCT00056368Candidiasis · United States3CompletedPfizer256
NCT00002446Candidiasis, Oral · United States, Barbados3CompletedMerck300
NCT00002399Candidiasis, Oral · United States, Argentina, Belgium and more2CompletedMerck500
NCT00002339Candidiasis · United States3CompletedPfizer100
NCT00002325Mycoses · United States–CompletedPfizer
NCT00002306Meningitis, Cryptococcal · United States–CompletedPfizer
NCT00002305Meningitis, Cryptococcal · United States, Canada–CompletedPfizer
NCT00002304Candidiasis · United States, Canada–CompletedPfizer
NCT00002294Meningitis, Cryptococcal · United States–CompletedPfizer
NCT00002282Candidiasis, Oral · United States–CompletedPfizer
NCT00002277Mycoses · United States3CompletedPfizer
NCT00002132Candidiasis · United States–CompletedJohnson & Johnson
NCT00002113Meningitis, Cryptococcal · United States–CompletedPfizer64
NCT00002112Candidiasis, Oral · United States–CompletedPfizer
NCT00002077Meningitis, Cryptococcal · United States–CompletedPfizer
NCT00002076Meningitis, Cryptococcal · United States–CompletedPfizer
NCT00002075Meningitis, Cryptococcal · United States–CompletedPfizer
NCT00002074Meningitis, Cryptococcal · United States, Canada–CompletedPfizer
NCT00002068Meningitis, Cryptococcal · United States, Canada–CompletedPfizer
NCT00002040Meningitis, Cryptococcal · United States–CompletedPfizer
NCT00002038Candidiasis · United States–CompletedPfizer
NCT00002010Meningitis · United States–CompletedPfizer
NCT00001017Meningitis, Cryptococcal · United States3CompletedPfizerJul 1991330

How it is read

Names in the registry

  • “Fluconazole”, 36 entries
  • “fluconazole”, 5 entries
  • “Fluconazole 400 mg”, 1 entry
  • “Diflucan®”, 1 entry
  • “Fluconazole 150mg Capsule Localized Originator”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.